Fluoropharma Medical Inc (FPMI) 0.5800 $FPMI
Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:21AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 10th in St. Louis, MO
Marketwire - Wed Jun 11, 8:47AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that new Phase II trial data related to its CardioPET clinical trial was presented at the Society of Nuclear Medicine and Molecular Imaging Annual meeting (SNMMI), held in St. Louis, MO.
World Market for Cardiovascular Diagnostics (Markets for ECG, Imaging, Cardiac POC, Contrast Agents and Cardiac Markers) 2012-2017
M2 - Fri Jun 06, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjjxbp/the_world_market) has announced the addition of the "The World Market for Cardiovascular Diagnostics (Markets for ECG, Imaging, Cardiac POC, Contrast Agents and Cardiac Markers)" report to their offering. This report, The World Market for Cardiovascular Diagnostics, provides the reader with an overview of the global cardiac diagnostics industry and the trends driving growth. Segments within the cardiac diagnostic market include: - Electrocardiography including ECG testing, stress testing, Holter monitoring, event monitoring and implantable loop. - Cardiac imaging including non-invasive X-Ray, MRI, CT, ultrasound, and nuclear cardiography; and invasive /cardiac catheterization/angiography, intravascular ultrasound, optical coherence technology and electrophysiology. - Cardiac point-of-care including cholesterol testing and coagulation testing - Cardiac markers - Cardiac contrast agents and radiopharmaceuticals For each of these segments, market size and forecast, along with compound annual growth rate is provided. Also included in the report are statistics influencing the industry, incidence of cardiac and related diseases worldwide, demographics, life expectancy, and company strategies. Information is presented as a global market. A market summary includes a total market analysis. Also included is a competitive analysis of leading cardiac diagnostic providers. Companies profiled in this report include: - Abbott Diagnostics - Acusphere - Alere - Analogic Corp - Bayer Healthcare - Bracco SpA - Cardinal Health - CardioDX - C.R. Bard - Danaher Corporation - dpiX - FluoroPharma Medical - GE Healthcare - Hitachi Medical Systems - Johnson & Johnson - King Pharmaceuticals - Nanosphere - PerkinElmer - Philips Healthcare - Roche Diagnostics - Shimadzu Corp - Siemens Medical Solutions - St Jude Medical - Terumo Medical - TomTec Imaging Systems - Toshiba - Trixell - Vascular Solutions - Vermillion - Volcano Key Topics Covered: Chapter One: Executive Summary Chapter Two: Industry Overview Chapter Three: Electrocardiography Chapter Four: Cardiac Diagnostic Imaging Chapter Five: Cardiac Diagnostic Point Of Care Testing Chapter Six: Cardiac Markers Chapter Seven: Cardiac Diagnostic Contrast Agents And Radiopharmaceuticals Chapter Eight: Market Participants Chapter Nine: Market Trends And Summary Chapter Ten: Industry Developments And Technologies Chapter Eleven: Conclusions For more information visit http://www.researchandmarkets.com/research/gj...rld_market
FluoroPharma Medical Announces Presentation of Data From Phase II Clinical Trial of 18F FCPHA (CardioPET) at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 7-14, in St. Louis, MO
Marketwire - Thu May 29, 7:34AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that data and analysis from a feasibility study on the quantification of myocardial perfusion in humans by PET/CT utilizing the fatty acid analogue 18F-FCPHA will be presented by the principal investigator, Olivier Gheysens, MD, PhD, at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.
FluoroPharma CEO Thijs Spoor to Be Interviewed Live Today on Clear Channel Business Talk Radio
Marketwire - Wed Apr 02, 7:16AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI) ("FluoroPharma"
, a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today its CEO, Thijs Spoor, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. Any interested parties may tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
FluoroPharma Announces Appointment of Andrew H. Sassine to the Board of Directors
Marketwire - Tue Mar 11, 6:33AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced the appointment of Andrew H. Sassine to the Board of Directors, effective April 1st.
Data Presented From FluoroPharma's Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Acute and Chronic Forms of Coronary Artery Disease (CAD)
Marketwire - Thu Feb 06, 11:58AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced the presentation of data from an ongoing Phase II clinical trial for 18F-FCPHA (CardioPET) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients.
FluoroPharma CEO, Thijs Spoor, to Present Business and Portfolio Updates at the Noble Financial Capital Markets' Tenth Annual Equity Conference January 20, 2014
Marketwire - Wed Jan 15, 12:02PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that Thijs Spoor, Chairman & CEO of FluoroPharma Medical, will present at the Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper, Florida on Monday, January 20th at 2:30PM Eastern Time in Room 1.
FluoroPharma CEO Thijs Spoor to Provide Business and Portfolio Update at Biotech Showcase 2014 in San Francisco, January 13th-15th
Marketwire - Wed Jan 08, 2:05PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that Thijs Spoor, Chairman and CEO of FluoroPharma Medical, will be presenting at the annual Biotech Showcase in San Francisco, at the Wyndham Hotel on Tuesday, January 14th. Mr. Spoor's presentation will take place at 2:00PM PST in the Powell Room.
FluoroPharma Medical Announces Acceptance of Abstract for Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Winter Meeting
Marketwire - Thu Dec 19, 6:30AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to announce that their Abstract has been accepted for oral presentation at the SNMMI winter meeting which will be held in conjunction with the Annual Meeting of the American College of Nuclear Medicine. Data from FluoroPharma's ongoing Phase II clinical trial for CardioPET (18F FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients, will be presented at the meeting scheduled for February 6-9 in Palm Springs, CA.
FluoroPharma Medical, Inc. Announces Closing of Equity Financing
Marketwire - Thu Sep 19, 6:14AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that it has entered into a securities purchase agreement with a number of new and existing accredited investors in connection with a private placement financing of up to $7,000,000 of its preferred shares. Platinum Montaur Life Sciences, LLC served as lead investor.
MediFocus: Future of Molecular Imaging
M2 - Thu Sep 12, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mzc6jd/medifocus_future) has announced the addition of the "MediFocus: Future of Molecular Imaging" report to their offering. Molecular imaging is at the frontier of diagnostic imaging. It is a vast and multi-disciplinary field that consists of a range of techniques, allowing imaging of various organs and sites within the body with specific targeted probes. Molecular imaging can be defined as 'the visualization, characterization and measurement of biological processes at the molecular and cellular levels in human and other living systems''. Although sluggish economic growth has hindered the growth of the molecular imaging market right from its inception in the leading economies of the world such as in the United States and Europe, the market has attracted attention from both academia and manufacturers in recent years. The need for less invasive imaging techniques and more specific imaging probes has fuelled continued development and ever-changing market competition with molecular imaging. "MediFocus: Future of Molecular Imaging". The report offers a comprehensive analysis of the molecular imaging market, including new imaging techniques and late-stage imaging probes. Included within is an analysis of companies currently active in the field with their commercial positioning and portfolio assessment. The report identifies and evaluates key trends and advances shaping the global molecular imaging market, highlighting testimonials from top physicians around the world. The report provides insight into the market opportunities, barriers and drivers within the market for the benefit of new companies willing to enter this market in the near future. Scope - An overview of the molecular imaging landscape - Investigation of current and future market competition for molecular imaging - Pipeline assessment with product profiles, SWOT analysis and commercial positioning - Evaluation of technology trends in molecular imaging and physician perception - Coverage of key market players with portfolio assessment and SWOT analysis - Direct quotes from Key Opinion Leaders (KOL) currently using and developing molecular imaging probes Companies Mentioned Navidea Biopharmaceuticals Lantheus Medical Imaging Mallinckrodt Pharmaceuticals Avid Radiopharmaceuticals (Eli Lilly) Bracco Imaging GE Healthcare Piramal Imaging Siemens Novelos Therapeutics Affibody Atreus Pharmaceuticals Kereos Progenics Pharmaceuticals FluoroPharma Medical Wilex For more information visit http://www.researchandmarkets.com/research/mz...cus_future About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FluoroPharma CEO Provides Shareholders With a "State of the Union" Communication
Marketwire - Mon Jul 29, 6:44AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today the release of a company overview as presented by FluoroPharma's President, CEO and Chairman of the Board, Thijs Spoor.
FluoroPharma Medical Announces Internal Review of Currently Acquired Imaging Data From Phase II Study for CardioPET(TM) (FCPHA)
Marketwire - Thu Jun 20, 8:03AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased with currently acquired imaging data from its ongoing Phase II clinical trial for CardioPETâ?¢ (FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients.
Market Trends Offer Opportunities for FPMI - Analyst Blog
Brian Marckx - Zacks Investment Research - Mon May 20, 4:01PM CDT
FluoroPharma Medical, Inc. (OTC BB:FPMI) seeks to develop breakthrough molecular imaging agents for positron emission tomography (PET) to fulfill critical medical needs.
FluoroPharma Medical's CEO and Chairman, Thijs Spoor, to Present at Taglich Brothers 10th Annual Small Cap Equity Conference on May 7th
Marketwire - Tue Apr 30, 6:09PM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that Thijs Spoor, Chairman & CEO of FluoroPharma Medical, will present at the Taglich Brothers 10th Annual Small Cap Conference at the New York Athletic Club in New York City on Tuesday, May 7, 2013.
Taglich Brothers Initiates Coverage on FluroPharma Medical, Inc.
PRWeb - Thu Apr 25, 9:04AM CDT
FluoroPharma Medical, Inc. announces Taglich Brothers has initiated coverage.
10th Annual Taglich Brothers Small Cap Equity Conference
GlobeNewswire - Wed Apr 24, 9:39AM CDT
via PRWEB - The 10th Annual Taglich Brothers Small Cap Equity Conference will be held in Manhattan at the New York Athletic Club on Tuesday, May 7th, 2013.
Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:21AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 10th in St. Louis, MO
Marketwire - Wed Jun 11, 8:47AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that new Phase II trial data related to its CardioPET clinical trial was presented at the Society of Nuclear Medicine and Molecular Imaging Annual meeting (SNMMI), held in St. Louis, MO.
World Market for Cardiovascular Diagnostics (Markets for ECG, Imaging, Cardiac POC, Contrast Agents and Cardiac Markers) 2012-2017
M2 - Fri Jun 06, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjjxbp/the_world_market) has announced the addition of the "The World Market for Cardiovascular Diagnostics (Markets for ECG, Imaging, Cardiac POC, Contrast Agents and Cardiac Markers)" report to their offering. This report, The World Market for Cardiovascular Diagnostics, provides the reader with an overview of the global cardiac diagnostics industry and the trends driving growth. Segments within the cardiac diagnostic market include: - Electrocardiography including ECG testing, stress testing, Holter monitoring, event monitoring and implantable loop. - Cardiac imaging including non-invasive X-Ray, MRI, CT, ultrasound, and nuclear cardiography; and invasive /cardiac catheterization/angiography, intravascular ultrasound, optical coherence technology and electrophysiology. - Cardiac point-of-care including cholesterol testing and coagulation testing - Cardiac markers - Cardiac contrast agents and radiopharmaceuticals For each of these segments, market size and forecast, along with compound annual growth rate is provided. Also included in the report are statistics influencing the industry, incidence of cardiac and related diseases worldwide, demographics, life expectancy, and company strategies. Information is presented as a global market. A market summary includes a total market analysis. Also included is a competitive analysis of leading cardiac diagnostic providers. Companies profiled in this report include: - Abbott Diagnostics - Acusphere - Alere - Analogic Corp - Bayer Healthcare - Bracco SpA - Cardinal Health - CardioDX - C.R. Bard - Danaher Corporation - dpiX - FluoroPharma Medical - GE Healthcare - Hitachi Medical Systems - Johnson & Johnson - King Pharmaceuticals - Nanosphere - PerkinElmer - Philips Healthcare - Roche Diagnostics - Shimadzu Corp - Siemens Medical Solutions - St Jude Medical - Terumo Medical - TomTec Imaging Systems - Toshiba - Trixell - Vascular Solutions - Vermillion - Volcano Key Topics Covered: Chapter One: Executive Summary Chapter Two: Industry Overview Chapter Three: Electrocardiography Chapter Four: Cardiac Diagnostic Imaging Chapter Five: Cardiac Diagnostic Point Of Care Testing Chapter Six: Cardiac Markers Chapter Seven: Cardiac Diagnostic Contrast Agents And Radiopharmaceuticals Chapter Eight: Market Participants Chapter Nine: Market Trends And Summary Chapter Ten: Industry Developments And Technologies Chapter Eleven: Conclusions For more information visit http://www.researchandmarkets.com/research/gj...rld_market
FluoroPharma Medical Announces Presentation of Data From Phase II Clinical Trial of 18F FCPHA (CardioPET) at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 7-14, in St. Louis, MO
Marketwire - Thu May 29, 7:34AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that data and analysis from a feasibility study on the quantification of myocardial perfusion in humans by PET/CT utilizing the fatty acid analogue 18F-FCPHA will be presented by the principal investigator, Olivier Gheysens, MD, PhD, at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.
FluoroPharma CEO Thijs Spoor to Be Interviewed Live Today on Clear Channel Business Talk Radio
Marketwire - Wed Apr 02, 7:16AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI) ("FluoroPharma"
, a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today its CEO, Thijs Spoor, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. Any interested parties may tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream. FluoroPharma Announces Appointment of Andrew H. Sassine to the Board of Directors
Marketwire - Tue Mar 11, 6:33AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced the appointment of Andrew H. Sassine to the Board of Directors, effective April 1st.
Data Presented From FluoroPharma's Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Acute and Chronic Forms of Coronary Artery Disease (CAD)
Marketwire - Thu Feb 06, 11:58AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced the presentation of data from an ongoing Phase II clinical trial for 18F-FCPHA (CardioPET) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients.
FluoroPharma CEO, Thijs Spoor, to Present Business and Portfolio Updates at the Noble Financial Capital Markets' Tenth Annual Equity Conference January 20, 2014
Marketwire - Wed Jan 15, 12:02PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that Thijs Spoor, Chairman & CEO of FluoroPharma Medical, will present at the Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper, Florida on Monday, January 20th at 2:30PM Eastern Time in Room 1.
FluoroPharma CEO Thijs Spoor to Provide Business and Portfolio Update at Biotech Showcase 2014 in San Francisco, January 13th-15th
Marketwire - Wed Jan 08, 2:05PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that Thijs Spoor, Chairman and CEO of FluoroPharma Medical, will be presenting at the annual Biotech Showcase in San Francisco, at the Wyndham Hotel on Tuesday, January 14th. Mr. Spoor's presentation will take place at 2:00PM PST in the Powell Room.
FluoroPharma Medical Announces Acceptance of Abstract for Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Winter Meeting
Marketwire - Thu Dec 19, 6:30AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to announce that their Abstract has been accepted for oral presentation at the SNMMI winter meeting which will be held in conjunction with the Annual Meeting of the American College of Nuclear Medicine. Data from FluoroPharma's ongoing Phase II clinical trial for CardioPET (18F FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients, will be presented at the meeting scheduled for February 6-9 in Palm Springs, CA.
FluoroPharma Medical, Inc. Announces Closing of Equity Financing
Marketwire - Thu Sep 19, 6:14AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that it has entered into a securities purchase agreement with a number of new and existing accredited investors in connection with a private placement financing of up to $7,000,000 of its preferred shares. Platinum Montaur Life Sciences, LLC served as lead investor.
MediFocus: Future of Molecular Imaging
M2 - Thu Sep 12, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mzc6jd/medifocus_future) has announced the addition of the "MediFocus: Future of Molecular Imaging" report to their offering. Molecular imaging is at the frontier of diagnostic imaging. It is a vast and multi-disciplinary field that consists of a range of techniques, allowing imaging of various organs and sites within the body with specific targeted probes. Molecular imaging can be defined as 'the visualization, characterization and measurement of biological processes at the molecular and cellular levels in human and other living systems''. Although sluggish economic growth has hindered the growth of the molecular imaging market right from its inception in the leading economies of the world such as in the United States and Europe, the market has attracted attention from both academia and manufacturers in recent years. The need for less invasive imaging techniques and more specific imaging probes has fuelled continued development and ever-changing market competition with molecular imaging. "MediFocus: Future of Molecular Imaging". The report offers a comprehensive analysis of the molecular imaging market, including new imaging techniques and late-stage imaging probes. Included within is an analysis of companies currently active in the field with their commercial positioning and portfolio assessment. The report identifies and evaluates key trends and advances shaping the global molecular imaging market, highlighting testimonials from top physicians around the world. The report provides insight into the market opportunities, barriers and drivers within the market for the benefit of new companies willing to enter this market in the near future. Scope - An overview of the molecular imaging landscape - Investigation of current and future market competition for molecular imaging - Pipeline assessment with product profiles, SWOT analysis and commercial positioning - Evaluation of technology trends in molecular imaging and physician perception - Coverage of key market players with portfolio assessment and SWOT analysis - Direct quotes from Key Opinion Leaders (KOL) currently using and developing molecular imaging probes Companies Mentioned Navidea Biopharmaceuticals Lantheus Medical Imaging Mallinckrodt Pharmaceuticals Avid Radiopharmaceuticals (Eli Lilly) Bracco Imaging GE Healthcare Piramal Imaging Siemens Novelos Therapeutics Affibody Atreus Pharmaceuticals Kereos Progenics Pharmaceuticals FluoroPharma Medical Wilex For more information visit http://www.researchandmarkets.com/research/mz...cus_future About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FluoroPharma CEO Provides Shareholders With a "State of the Union" Communication
Marketwire - Mon Jul 29, 6:44AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today the release of a company overview as presented by FluoroPharma's President, CEO and Chairman of the Board, Thijs Spoor.
FluoroPharma Medical Announces Internal Review of Currently Acquired Imaging Data From Phase II Study for CardioPET(TM) (FCPHA)
Marketwire - Thu Jun 20, 8:03AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased with currently acquired imaging data from its ongoing Phase II clinical trial for CardioPETâ?¢ (FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients.
Market Trends Offer Opportunities for FPMI - Analyst Blog
Brian Marckx - Zacks Investment Research - Mon May 20, 4:01PM CDT
FluoroPharma Medical, Inc. (OTC BB:FPMI) seeks to develop breakthrough molecular imaging agents for positron emission tomography (PET) to fulfill critical medical needs.
FluoroPharma Medical's CEO and Chairman, Thijs Spoor, to Present at Taglich Brothers 10th Annual Small Cap Equity Conference on May 7th
Marketwire - Tue Apr 30, 6:09PM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that Thijs Spoor, Chairman & CEO of FluoroPharma Medical, will present at the Taglich Brothers 10th Annual Small Cap Conference at the New York Athletic Club in New York City on Tuesday, May 7, 2013.
Taglich Brothers Initiates Coverage on FluroPharma Medical, Inc.
PRWeb - Thu Apr 25, 9:04AM CDT
FluoroPharma Medical, Inc. announces Taglich Brothers has initiated coverage.
10th Annual Taglich Brothers Small Cap Equity Conference
GlobeNewswire - Wed Apr 24, 9:39AM CDT
via PRWEB - The 10th Annual Taglich Brothers Small Cap Equity Conference will be held in Manhattan at the New York Athletic Club on Tuesday, May 7th, 2013.
